Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | AGBL2 | Q5U5Z8 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2838831 | 0.84 | ALDH1A1 (0.50) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL4368849 | 0.75 | AGBL2 (0.44) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL18376268 | 0.75 | IL1B (0.49) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL15945544 | 0.71 | POLB (0.46) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL6985291 | 0.70 | AGBL2 (0.45) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL15922616 | 0.69 | SMN1; SMN2 (0.53) | GAAALDH1A1AGBL2SMN1; SMN2RAB9A | |
| SCHEMBL30366829 | 0.68 | CA1 (0.56) | L3MBTL1POLBALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL24612069 | 0.67 | CFTR (0.49) | L3MBTL1GAAPOLBALDH1A1AGBL2 | |
| SCHEMBL30366730 | 0.67 | ALDH1A1 (0.61) | L3MBTL1GAAALDH1A1SMN1; SMN2RAB9A | |
| SCHEMBL14783550 | 0.66 | CFTR (0.65) | GAAPOLBALDH1A1AGBL2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2010-07-01 | — | — | US | disclosed |
| US-7696231-B2 | Oxindole hydrazide modulators of protein tyrosine phosphatases (PTPs) | LABORATOIRES SERONO SA (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. | 2005-02-24 | — | — | US | disclosed |
| EP-1439834-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | Applied Research Systems ARS Holding N.V. (AN) | 2004-07-28 | — | — | EP | disclosed |
| WO-2003037328-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043388-A1 | Oxindole hydrazide modulators of protein tyrosine phosphatases (ptps) | PTPRO, PTPRE, PTPRZ1 | L3MBTL1 4356/4885GAA 2360/4885POLB 4789/4885 |
| US-20100168101-A1 | OXINDOLE HYDRAZIDE MODULATORS OF PROTEIN TYROSINE PHOSPHATASES (PTPS) | PTPRO, PTPRE, PTPRZ1 | L3MBTL1 4364/4885GAA 2377/4885POLB 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.